The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

quaypharma.com

Stage

Acquired | Acquired

About Quay Pharma

Quay Pharma is a pharmaceutical contract development and manufacturing organization. It is based in Deeside, Wales.On December 7th, 2021, Quay Pharma was acquired by SGS. Terms of the transaction were not disclosed.

Quay Pharma Headquarter Location

28 Parkway Deeside Industrial Park

Deeside, Wales,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Quay Pharma News

SGS Quay Pharma Partners with Liveome to Develop & Commercialize LIV001

Apr 12, 2022

SGS Quay Pharma Partners with Liveome to Develop & Commercialize LIV001 LIV001 is a candidate for the treatment of inflammatory bowel disease. SGS Quay Pharma was selected for this project because of its proven expertise in product development and clinical supply for therapies derived from the microbiome. 04.12.22 Contract development and manufacturing organization (CDMO) SGS Quay Pharma has signed a contract with Korean drug development specialist Liveome for the formulation development and clinical manufacture of a targeted release formulation for the treatment of inflammatory bowel disease containing lyophilized microbial cells suitable for phase one clinical trials. The drug substance is being supplied by Australia-based Luina Bio. “Starting with these CDMO contracts for LIV001, we plan to build a cell bank, develop a production process, and produce clinical samples,” Liveome CEO Song Ji-yoon said. “We aim to complete a nonclinical toxicity test this year and start a global clinical trial by 2023.”   SGS Quay Pharma was selected for the project because of the company’s proven expertise in product development and clinical supply for therapies derived from the microbiome, which includes not only microbes but also small and large molecules that require targeted delivery throughout the body. Quay is licensed for the support of oral drug products manufactured utilizing live biotherapies. The company’s expertise in this area is based on its breadth of expertise in formulation development across many delivery routes, along with its understanding of isolation and containment techniques to protect the environment during the manufacturing process. In particular, Quay has introduced procedures to effectively handle many types of microbes during the development and manufacture of drug products in order to maintain their potency. “We are delighted to be working on this important project,” commented SGS Quay Pharma’s commercial operations director, Maireadh Pedersen. “Our appointment by Liveome underlines not only our development and manufacturing capabilities in this significant new sector, but also our ability to deliver our services globally and continue to grow our support of the South Korean market.”   Quay’s advanced manufacturing facilities at its Quay House facilities in Deeside, UK, include a suite of laboratories with a compartmentalized design to containment Level 2, enabling the company to work on a variety of projects and different microbes simultaneously. Established last year, Liveome, a subsidiary of Medytox, specializes in the development of next-generation new drugs. It recently confirmed the therapeutic efficacy of LIV001 for acute and chronic enteritis through a preclinical trial. 03.24.22 03.21.22 03.18.22 03.08.22 03.01.22 02.10.22 02.01.22 12.14.21 12.01.21 11.11.21 10.21.21 10.18.21 10.08.21 09.21.21 09.13.21

Quay Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Quay Pharma Rank

  • Where is Quay Pharma's headquarters?

    Quay Pharma's headquarters is located at 28 Parkway, Deeside.

  • What is Quay Pharma's latest funding round?

    Quay Pharma's latest funding round is Acquired.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.